Current Status of Endolysin-Based Treatments against Gram-Negative Bacteria

• Published in: Antibiotics
• Main Authors: Marco Túlio Pardini Gontijo, Genesy Perez Jorge, Marcelo Brocchi
• Format: Article
• Language: English
• Published: MDPI AG 2021-09-01
• Subjects: nosocomial pathogen; bacteriophage; enzybiotic; peptide tag; bactericidal activity; biocontrol
• Online Access: https://www.mdpi.com/2079-6382/10/10/1143

The prevalence of multidrug-resistant Gram-negative bacteria is a public health concern. Bacteriophages and bacteriophage-derived lytic enzymes have been studied in response to the emergence of multidrug-resistant bacteria. The availability of tRNAs and endolysin toxicity during recombinant protein expression is circumvented by codon optimization and lower expression levels using inducible pET-type plasmids and controlled cultivation conditions, respectively. The use of polyhistidine tags facilitates endolysin purification and alters antimicrobial activity. Outer membrane permeabilizers, such as organic acids, act synergistically with endolysins, but some endolysins permeate the outer membrane of Gram-negative bacteria <i>per se</i>. However, the outer membrane permeation mechanisms of endolysins remain unclear. Other strategies, such as the co-administration of endolysins with polymyxins, silver nanoparticles, and liposomes confer additional outer membrane permeation. Engineered endolysins comprising domains for outer membrane permeation is also a strategy used to overcome the current challenges on the control of multidrug-resistant Gram-negative bacteria. Metagenomics is a new strategy for screening endolysins with interesting antimicrobial properties from uncultured phage genomes. Here, we review the current state of the art on the heterologous expression of endolysin, showing the potential of bacteriophage endolysins in controlling bacterial infections.